

Whole Exome Sequencing Test

Institution		Lab No.	
Name		Age/Gender	
Accession No.		Sample type	Whole Blood
Department/Doctor	/	Received /Reported	

Indication : Severe hemolytic anemia, cholestasis, liver failure

Test Result (The variant related to patient's clinical phenotype)

(This result is the final report.)

Variant	The aberration was detected, related to patient's clinical phenotype.
----------------	--

Type of variant

Gene	DNA change	Predicted AA change	Zygoty	Disease	Inherit	Class
PKLR	c.283+1914_1434del	p.(?)	Homo	PK deficiency Reference sequence: NG_011677.1(NM_000298.6)	AR	Pathogenic
Abbreviations: Homo= Homozygous; PK= pyruvate kinase; AR= Autosomal recessive						

Interpretation

Whole exome sequencing analysis identified a homozygous pathogenic copy number aberration in the PKLR gene associated with red cell pyruvate kinase (PK) deficiency.

The c.283+1914_1434del is a deletion of 5,006 base pairs extending from intron 2 to almost the 3' end of exon 9 of the PKLR gene. The aberration has previously been reported in the pyruvate kinase deficiency patients (PMID: 15642665 described as PK Viet del 4-10; PMID: 15953013 described as del 5006bp IVS3--> nt 1431; PMID: 22183074 described as c.283+1914_c.1434del5006).

The PKLR is a causative gene of autosomal recessive red cell pyruvate kinase (PK) deficiency. Genetic counseling for the patient is recommended and further genetic analysis to check the carrier status of the parents would be helpful for family planning.

* NGS analysis found that no sequence read was aligned from exon 3 to exon 9 of the PKLR gene, which indicated a homozygous deletion of that region. Gap-PCR followed by Sanger sequencing confirmed the finding and characterized the deletion margin. Primers described in the previous report were used (PMID: 22183074).

Whole Exome Sequencing Test

Institution		Lab No.	
Name		Age/Gender	
Accession No.		Sample type	Whole Blood
Department/Doctor	/	Received /Reported	

Whole Exome sequencing Methods

Genomic DNA was extracted from EDTA whole blood and we captured all the exons of human genes using SureSelectXT Human All Exome v5 (Agilent). For massively parallel sequencing, the post-capture library DNA was used to perform sequence analysis on Illumina NextSeq platform with 150 bp paired end reads. The DNA sequence was mapped to, and analyzed in comparison with, the public human genome build (UCSC hg19 reference). All reportable sequence variants were confirmed by Sanger sequence analysis.

Mean depth of coverage	115X
% of > 10x	97.2%

Limitation of the test

In the case of not detecting pathogenic genes' reasonable variants on disease phenotypes by sequencing, this test could not exclude any genetic factors related with patient's health conditions. Some types of genetic abnormalities, such as copy number changes, may not be detectable with the technologies performed by this analysis.

It is possible that the genomic region where a disease causing mutation exists in the proband was not captured using the current technologies and therefore was not detected.

GRGF-001 Rev.(0) 2014.4.1

Medical Technologist:

Min-Jeong Kim M.T.(37668)

Lab Director(medical doctor):

Ja-Hyun Jang M.D.(822)



Jong-Mun Choi M.D.(924)



107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do,
16924 Republic of Korea

Tel: +82 31-280-9939

Fax. 031-260-9087

www.gcgenome.com/eng